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Abstract
Background: Uterine fibroids are common among women at the reproductive age. Magnetic resonance-guided
focused ultrasound surgery (MRgFUS) is a novel and a conservative treatment for symptomatic cases. The aim
of the study was to evaluate the efficacy of MRgFUS in African-American (AA) women compared with that in
non-African-Americans (non-AA).
Methods: A single-armed phase IV study was conducted to establish the efficacy of treatment in AA women.
Comparison of patient, fibroid, and treatment characteristics from this trial was compared with that of the previously
published phase III trial. Both studies were approved by the IRB of each medical center.
Results: Sixty-three AA and 59 non-AA women were treated with MRgFUS. Although AA women had a different
pattern of disease, outcomes were similar in both groups. AA patients had a significant higher total number of fibroids
compared with non-AA (median 6.0, interquartile range (IQR) 3.0–10.0 vs. 2.0, IQR 1.0–4.0, respectively, p < 0.001),
although their total fibroid volume was significantly smaller (median 196.9 cm
3,I Q R1 1 2 . 8 –415.3 cm
3 vs. 394.8 cm
3,I Q R
189.8–674.4 cm
3, respectively, p < 0.001). AA women were younger compared with non-AA (mean ± SD 43.4 ± 5.1 vs.
46.3 ± 4.1 years of age, respectively, p = 0.001) when they presented for treatment. The rate of alternative treatments as
well as fibroid-associated symptoms at follow-up time points (3, 6, 12, 24, and 36 months, period following MRgFUS
treatment) did not differ according to race (p ≥ 0.62).
Conclusion: Despite differences in the pattern of fibroid disease, MRgFUS for uterine fibroids has a similar efficacy for
AA women compared with non-AA women.
Keywords: MRgFUS, Fibroids, Leiomyoma, African-American, Alternative treatment
Background
Uterine fibroids (leiomyomas or myomas) are an import-
ant healthcare issue, chiefly because of their frequency,
associated morbidity, and their contribution to the rate
of hysterectomy [1,2]. Hysterectomy rates have declined
in recent years in part due to the increasing array of
minimally invasive alternatives to hysterectomy utilized
for fibroid treatment including laparoscopic, hystero-
scopic, and robotic myomectomy, endometrial ablation,
uterine artery embolization (UAE), and magnetic reson-
ance imaging (MRI)-guided focused ultrasound surgery
(MRgFUS) as well as medical treatments [3,4].
Uterine fibroids have significant health disparities
for African-American (AA) women. Compared to other
women, AA women have evidence of a more extensive pat-
tern of fibroids and an earlier age of onset [5-8]. Genetic
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contribute to this racial disparity [9-12]. Despite this dis-
parity, most studies of fibroid treatment have not reported
the racial composition of enrolled participants, and studies
that do report race often have few AA women [13].
MRgFUS is a Food and Drug Administration (FDA)-
approved therapy for uterine leiomyomas that has been
demonstrated in multiple reports to result in sustained
treatment efficacy [14-20]. Early cohorts studied with this
treatment were largely non-AA. In light of this reality, the
primary purposes of this report were to evaluate the effi-
cacy of MRgFUS in AA women relative to non-AA women
and to determine the risk of adverse effects in the AA
population. A secondary goal was to compare the pattern
of fibroids in AA women enrolled in this study to that in
other women enrolled in a previous clinical trial of
MRgFUS that had the same enrollment criteria [21].
Methods
All data on AA women was collected as part of a phase
IV, non-randomized, multicenter clinical trial designed
to evaluate the safety and effectiveness of MRgFUS treat-
ment in this specific high-risk population. Funding was
provided by the device manufacturer (InSightec, Haifa,
Israel), and the protocol was approved by each local in-
stitutional review board.
Women were treated between January 2005 and April
2006 at one of nine US clinical centers (Brigham and
Women’s Hospital (BWH), Boston, MA, USA; Mayo
Clinic, Rochester, MN, USA; Johns Hopkins Hospital,
Baltimore, MD, USA; Radnet, Beverly Hills, CA, USA;
Lahey, Burlington, MA, USA; Sightline, Houston, TX,
USA; North Texas Uterine Fibroid Institute, Dallas, TX,
USA; UMRI Boca Raton, FL, USA; and Virtua, Voorhees,
NJ, USA). Because the enrollment criteria and treatment
guidelines were identical to the earlier phase III multi-
center clinical trial that led to the approval of this de-
vice, we utilized, as a comparison group, the data from
this published clinical trial, whose patients were treated
between April 2004 and January 2005 [21]. Both clinical
studies were approved by the IRB from each site.
The eligibility criteria for both trials have been previously
described [14,19,21]. Briefly, subjects were premenopausal
women in good general health, with symptomatic uterine
fibroids, and who had no future childbearing plans.
Enrollment and screening
Patients seeking treatment for symptomatic uterine fi-
broids at one of nine US clinical centers were recruited
through the gynecology and interventional radiology
clinics. Flyers, posters, and local advertisements were used
as recruitment tools. Eligible premenopausal women were
asked to complete a validated Symptom Severity Score
(SSS) from the uterine fibroid symptom and quality of life
(UFS-QOL) questionnaire [22]. The scores were trans-
formed to create a transformed SSS, yielding a 0 to 100
point scale with higher scores indicating worse symptoms
[22]. Patients with SSS ≥ 41 (i.e., symptomatic uterine
fibroids) were scheduled for a medical and gynecological
assessment. If there were no significant medical con-
traindications for treatment (such as claustrophobia,
severe hypertension, severe cerebrovascular disease, severe
anemia, clotting disorders, or MR contraindications such
as a cardiac pacemaker or other metallic devices, signifi-
cant anterior abdominal scarring, high BMI, etc.), a pelvic
MRI with intravenous gadolinium contrast was performed.
MR images were analyzed to determine the number, size,
and location of the fibroids. The enhancement patterns
were also assessed on the post-contrast images. Screen fail-
ures were defined as women with symptomatic uterine fi-
broids who were interested in MRgFUS treatment but
were not eligible due to one of the following: inadequate
fibroid-associated symptoms, a medical history that was a
contraindication for the treatment or imaging-associated
reasons, or MR findings such as necrotic fibroid, extensive
adenomyosis, multiple small (<3 cm) fibroids or single fi-
broids over 8 cm, and ones with large bowel loops inter-
posed between the uterus and anterior abdominal wall.
Equipment
The MRgFUS system (ExAblate 2000, InSightec, Haifa,
Israel) integrates a standard 1.5-T MRI system (GE Med-
ical Systems, Milwaukee, WI, USA) with the focused ultra-
sound treatment transducer housed in a water bath within
the MR table. The MR imaging system, described in detail
by Tempany et al. [20] and Stewart et al. [14], provides
real-time feedback of the temperature changes by incorp-
orating MR thermometry that uses sensitive imaging se-
quences during each sonication.
Patient preparation and treatment
Patient preparation has been previously described [20,21,23].
T2-weighted pelvic MR images were acquired and used
for treatment planning. A region of treatment was de-
fined within the fibroid on coronal imaging, and the num-
ber of spots (sonications) required to ablate this volume
was calculated by the treatment software. Each sonication
of focused ultrasound energy targeted an approximately
1-cm
3 bean-shaped region. The sonication could be al-
tered in power, frequency, diameter, and length to allow
a great treatment volume as safely as possible using as
few sonications as possible. Once planning was complete,
low-energy test sonications were delivered to confirm
correct sonication location. The power was then increased
until the temperature-sensitive maps demonstrated a ther-
apeutic thermal focus. Treatment failure was defined
as a treatment in which fewer than ten sonications were
performed.
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contrast-enhanced T1-weighted MRI with IV administra-
tion of gadolinium (gadopentetate dimeglumine) and the
resultant volume of non-enhancing tissue (non-perfused
volume (NPV)) was measured. The NPV ratio to treated fi-
broid volume and NPV ratio to total fibroid volume were
determined. In cases of patients who underwent two treat-
ments, the NPV in the study was the total NPV achieved
following the second MRgFUS treatment. The volume of
treated fibroids was calculated from MRI images at 6 and
12 months after the treatment and compared with baseline.
Treatment protocols
The goal of treatment was to deliver the therapeutic soni-
cations to as large fibroid area as possible, within the limi-
tation of the clinical trial rules. All patients were treated
according to similar guidelines, as outlined by Fennessy
et al. [21]. Treatment was limited to 50% of fibroid volume
(except 33% if submucosal) or 150-cm
3 maximum vol-
umes. Maximum treatment time (from the first to the last
sonication) was 180 min. In cases where a second treat-
ment was deemed necessary, the second treatment was
performed within a 14-day period.
Data collection
Patient’s age, body mass index (BMI; kg/m
2), race, total
fibroid number, total fibroid volume (cm
3), and volume of
the treated fibroid(s) (cm
3) were all prospectively collected.
The patient’s race was self-defined, in keeping with the
FDA’s recommendation, for the collection of race and eth-
nicity data in clinical trials [24]. Patients were categorized
as AA if it was their only declared race. All others were
classified as non-AA. Patients were followed for up to 36
months after treatment. At 1 week and 3 months post-
procedure, a phone interview was conducted, and at 6, 12,
24, and 36 months, a face-to-face interview was conducted
to obtain an updated UFS-QOL SSS score. Also, at 6 and
12 months, a clinical evaluation and pelvic MRI were ob-
tained to measure the volume of the treated fibroids.
Adverse events
All adverse events (AEs) were reported to the institutional
review board and the US Food and Drug Administration
as required. AEs were reported by the patients and then
classified as serious or non-serious. Serious AEs were de-
fined according to the Standard Code of Federal Regulation
definitions for use of an investigational device [25]. In cases
of non-serious AEs, the reported complaints were further
classified as important (lasting for >14 days) or not import-
ant (lasting for less than 14 days).
Screen failures
A subanalysis of the patients who were declared screen
failures was conducted to compare the incidence and
reasons for screen failure between AA and non-AA women
using the data from the BWH site only (N = 39).
Statistical analysis
Statistical analyses were conducted using Statistical Ana-
lysis Software (SAS®) version 9.1 (SAS Institute, Inc.,
Cary, NC, USA). The Mann–Whitney-Wilcoxon test, a
two-sided non-parametric test for two independent sam-
ples, was used to study unadjusted differences in base-
line and treatment characteristics between the two racial
groups. To compare each group’s trajectory of outcomes
over time, the correlation between measures from the
same individual must be accounted for. Therefore, a gen-
eralized estimating equation with a binomial distribution,
a logit link, and compound symmetry covariance structure
were used for dichotomous outcomes (alternative treat-
ments), and mixed models with an unstructured covari-
ance structure were used for continuous outcomes (QOL
score, volume of treated fibroids). The models were ad-
justed for age and BMI.
A chi-square test was used to compare the propor-
tion of AEs in each group. Among women with at least
one AE, the numbers of AEs were compared using the
Mann–Whitney-Wilcoxon test. Data are presented as
mean ± SD for normally distributed variables and median
and 25th–75th percentile (interquartile range (IQR)) for
non-normally distributed variables.
Results and discussion
Patients
One hundred and thirty-seven women (mean age 44.8 ±
4.8, range 34–53 years) comprised our study population,
all of whom had MRgFUS fibroid treatment. There were
64 patients included from the phase III comparison
study, 62 of these were non-AA. The remaining 73 women
were from the phase IVAA study. Fifteen patients were ex-
cluded from the final analysis: four were treatment failures,
two AA patients who were treated as part of the phase III
study, four patients had adenomyosis, and five patients had
missing data (one patient had missing treatment MRI data,
two patients had missing post-treatment data, and two pa-
tients had all imaging data missing).
The final eligible study population comprised 122
women. Of these, 63 were AA and 59 non-AA. Among
the non-AA women, 58 defined themselves as white and
one as Hispanic. The AA women were significantly youn-
ger than the non-AA (mean ± SD 43.4 ± 5.1 vs. 46.3 ± 4.1
years of age, p = 0.001) and had a significantly higher BMI
(27.7 ± 4.9 kg/m
2 vs. 25.9 ± 4.2 kg/m
2, p = 0.03). The AA
women also had a significantly higher total number of fi-
broids (median 6.0, IQR 3.0–10.0 vs. 2.0, IQR 1.0–4.0, re-
spectively). Total fibroid volume of the AA compared to
the non-AA was smaller (median 196.9 cm
3, IQR 112.8–
415.3 cm
3 vs. 394.8 cm
3, IQR 189.8–674.4 cm
3, p < 0.001)
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tween the groups.
Treatment volumes
The volume of treated fibroids was significantly lower
among the AA compared with the non-AA (177.9 ±
162.4 cm
3 vs. 408.5 ± 286.6 cm
3, p < 0.0001). The mean
number of treated fibroids (per patient) was higher
among the AA compared with non-AA patients (1.6 ±
0.8 vs. 1.3 ± 0.6, p = 0.01) (Table 1). Although the NPV
ratio per treated fibroid was higher among AA women
(40.6% ± 25.4% vs. 29.9% ± 23.8%, p = 0.03), there was no
significant difference in the mean NPV per total fibroid vol-
ume at the end of treatment. The volume of treated fibroids
at 6 and 12 months after treatment and compared with
baseline is shown in Figure 1. Regardless of race, the mean
volume of treated fibroids decreased significantly over time
(p < 0.0001 for the AA and p = 0.002 for the non-AA).
Adverse events
A total of 128 AEs were recorded for the 65 patients in
both studies: 63 AEs were reported among AA and 65
Table 1 Demographic and treatment characteristics of AA and non-AA women with symptomatic uterine fibroids
treated by MRgFUS
Characteristics AA (n = 63) Non-AA (n = 59) p value
a
Age
0.001
Mean (SD) 43.4 (5.1) 46.3 (4.1)
Median (Q1–Q3) 44.0 (40.0–47.0) 46.0 (44.0–49.0)
Min.–max. 34.0–53.0 38.0–53.0
Body mass index (kg/m
2)
0.03
Mean (SD) 27.7 (4.9) 25.9 (4.2)
Median (Q1–Q3) 27.3 (24.1–30.6) 25.3 (22.5–28.4)
Min.–max. 18.2–40.7 19.1–39.5
Total number of fibroids
<0.001
Mean (SD) 7.2 (5.4) 2.8 (2.3)
Median (Q1–Q3) 6.0 (3.0–10.0) 2.0 (1.0–4.0)
Min.–max. 1.0–30.0 1.0–11.0
Total volume of fibroids (cm
3)
<0.001
Mean (SD) 273.0 (216.0) 449.6 (299.6)
Median (Q1–Q3) 196.9 (112.8–415.3) 394.8 (189.8–674.4)
Min.–max. 15.7–807.2 18.1–1518.4
Number of treated fibroids
0.01
Mean (SD) 1.6 (0.8) 1.3 (0.6)
Median (Q1–Q3) 1.0 (1.0–2.0) 1.0 (1.0–1.0)
Min.–max. 1.0–4.0 1.0–4.0
Total volume of treated fibroids (cm
3)
<0.001
Mean (SD) 177.9 (162.4) 408.5 (286.6)
Median (Q1–Q3) 130.0 (64.6–235.0) 366.6 (183.7–564.0)
Min.–max. 15.7–700.0 18.1–1518.4
NPV ratio per total fibroid
0.52
Mean (SD) 28.2 (20.0) 26.3 (20.7)
Median (Q1–Q3) 26.0 (15.3–41.0) 21.0 (9.0–42.0)
Min.–max.ds 0.0–81.4 0.0–79.0
NPV ratio per treated fibroid
0.03
Mean (SD) 40.6 (25.4) 29.9 (23.8)
Median (Q1-Q3) 37.6 (25.6–55.1) 27.3 (9.3–48.0)
Min.–max. 0.0–91.2 0.0–94.0
aTwo-sided Mann–Whitney-Wilcoxon p values. NPV non-perfused volume.
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reported. Non-AA patients reported more AEs following
treatment compared with AA. Among the non-AA, 47/59
(79.7%) reported at least one AE vs. 18/63 (28.6%) reported
in AA patients (p < 0.0001). Among those who reported
AEs, there was no significant difference in the number of
AEs per patient reported (2.0 ± 1.5 and 1.8 ± 1.0, non-AA
vs. AA).
The common types of AEs reported for both groups
were back/leg pain (21.9%), abdominal cramping (21.1%),
urinary tract infection/irritation symptoms (11.7%), gastro-
intestinal complaints (11.7%), skin irritation (7.0%), and va-
ginal bleeding or discharge (6.3%).
Clinical outcome
One hundred and twenty patients (98%), 111 (91%), 91
(74.6%), 64 (52.4%), and 49 (40.2%) were followed to ob-
tain their transformed SSS scores at 3, 6, 12, 24, and 36
months, respectively. The transformed SSS score signifi-
cantly decreased over time for both groups of patients
(both p < 0.0001). For the AA patients, median (IQR)
transformed SSS scores were 68.8 (50.0–81.3) at base-
line, 32.8 (12.5–46.9) at 12 months, 28.1 (9.4–43.8) at 24
months, and 12.5 (6.3–37.5) after 36 months. For the
non-AA patients, transformed SSS scores were 59.4
(50.0–78.1) at baseline, 31.3 (18.8–43.8) at 12 months, 26.6
(9.4–43.8) at 24 months, and 18.8 (12.5–40.6) after 36
months. There was no difference between the groups for
the rate of transformed QOL decrease (p = 0.62; Figure 2).
Transformed SSS at 36 months was static, although data
were available only for a small number of patients. The ac-
cumulated alternative treatments at the 6, 12, 24, and 36
months period following MRgFUS treatment were 4/115
(3.5%), 12/103 (11.7%), 32/96 (33.3%), and 42/91 (46.2%),
respectively. The rate of alternative treatments at follow-up
time points did not differ according to race (Table 2).
Analysis of screen failures in a subpopulation
In a subanalysis, we compared the rates and the reasons
for screen failures between AA women and non-AA
women who sought MRgFUS treatment as a part of these
clinical trials at a single institution. A total of 94 subjects
provided informed consent for MRgFUS studies (40 AA
and 54 non-AA) at the BWH site. Thirty-nine women
( 4 1 . 4 % )f a i l e dt om e e to n eo rm o r ee n r o l l m e n tc r i t e r i aa n d
were deemed screen failures.
AA women were more likely to be screen failures (52.5%
AA vs. 33.3% non-AAs, p = 0.06). The reasons for screen
failure differed significantly between groups. AA patients
were more likely to fail the screening due to MRI findings
that indicated that safe delivery of treatment was not pos-
sible, such as significant anterior abdominal wall scarring
or bowel in the anterior ultrasound beam path (76.2% AA
vs. 38.9% non-AA). However, they were less likely to fail
screening due to inadequate fibroid-associated symptoms
compared with the non-AA population (9.5% non-AA vs.
44.4% AA). Among the screen failures, AA patients had a
higher mean number of fibroids at screening MRI (11.7 ±
11.8 AA vs. 4.4 ± 3.5 non-AA, p = 0.05) and their fibroid
diameter was significantly smaller (median 2.4 cm, IQR
1.9–4.3 vs. 5.7 cm, IQR 4.9–7.4 cm, respectively, p < 0.01)
compared with that of non-AA women.
This study demonstrates similar safety and efficacy of
MRgFUS treatment for symptomatic uterine fibroids for
all women, regardless of self-reported race. AA women
present earlier for treatment with greater symptoms by
age and have a larger number and smaller size fibroids.
It has already been demonstrated that AA patients have
larger uteri and a greater fibroid burden [5]. Our subanaly-
sis at a single institution indicates AA to have a higher
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with fewer and larger fibroids among non-AA, suggesting
a different pattern of disease for AA. Despite the differ-
ences in presentation, once they passed screening and were
treated with MRgFUS, the two groups do not differ in
terms of their need for surgical intervention for failed
MRgFUS treatment and in terms of their overall symptom
improvement and fibroid shrinkage.
MRgFUS is an ambulatory, non-invasive technique for
the treatment of uterine fibroids with a high safety pro-
file [14] that enables patients to return to their routine
daily activities rapidly, either on the day of the treatment
or the day after [26]. Previous studies showed that high-
intensity focused ultrasound energy generated by MRgFUS
to ablate uterine fibroids can clinically improve and shrink
the fibroid without significant AEs [26]. Other trials
have reported significant long-term reductions in fibroid-
associated symptoms [14,27].
Considering the prevalence of fibroids in the AA popu-
lation, the severity of their disease, and the high rates of
hysterectomy and associated complications [28-33], it is
important to understand that MRgFUS is a viable treat-
ment option for this population from both a medical and
a cost perspective. Three studies to date investigated the
effect of uterine-preserving treatment for uterine fibroids
[33-35], although none evaluated the potential differential
effects between racial groups. We observed that at the
time of enrollment, AA patients were younger, had more
symptomatic fibroids (higher SSS QOL), and presented
with different fibroid MR characteristics compared with
non-AA patients (Table 1), which is consistent with previ-
ous studies [5,34,35].
The need for subsequent alternative treatments was
similar for AA and non-AA, and the frequency was simi-
lar to those reported elsewhere during the 6 and 12
months post-treatment [36]. Okada et al. reported a 4%
re-intervention rate after 6 months and 9% re-intervention
rates by 12 months in a population of 228 women treated
with MRgFUS in four medical centers in Japan between
2003 and 2006 [36]. Combining the results from the phase
III and phase IV studies, both the short-term alternative
treatment frequency (<12 months) and long-term alterna-
tive treatment rates were relatively high. In both groups,
the intervention rates 1 year or less following the treatment
was 11.6% compared with the 6.6% reported by Okada
et al. [36]. We reported alternative treatment rates of
33.3% and 46.1%, respectively, 2 and 3 years after the clin-
ical studies. Intervention rates did not differ between the
groups. The mean NPV achieved for both groups in our
study was around 20%, which is similar to the NPV
achieved in other early clinical trials [15,36]. This is a very
low NPV, compared with the higher rates now being
achieved with more current technology [36,37]. Previous
studies have noted that higher NPV at the end of the treat-
ment is associated with treatment success. It is important
to note that our studies were carried out under restricted
clinical trial guidelines leading to these low NPVs and these
treatment limitations are not in place today.
The higher screen failure rate among AA found in our
study should be the subject of future studies with higher
numbers of patients. As our numbers were relatively
small, it is possible that our findings were secondary to
sample size. Today, as the enrollment criteria are less re-
strictive, it remains to be seen if the high screen failure
rate persists.
Conclusion
We conclude that MRgFUS treatment is a safe and ef-
fective uterine-sparing treatment option for AA women.
Further studies including longer follow-up of patients
achieving higher NPV at the end of the treatment are
needed to assess the long-term outcomes of the proced-
ure among all women classified by race.
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